Results 221 to 230 of about 692,269 (276)

E3 Ubiquitin Ligases in MASH‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) is a major cause of progressive liver fibrosis and can ultimately lead to cirrhosis and hepatocellular carcinoma (HCC). MASH‐associated liver fibrosis develops through a complex interplay among lipotoxic hepatocyte injury, oxidative and endoplasmic reticulum stress, inflammatory ...
Ah‐Reum Oh, Yelin Jeong, Young Hoon Jung, Young Un Kim, HyunJoon Gi, Do‐Wan Kim, Young Du Choi, Sang Bae Lee, KyeongJin Kim   +8 more
wiley   +1 more source

MDM2/X mediates reduced apoptosis in the plateau zokor: a mechanism of high-altitude adaptation. [PDF]

J Zhejiang Univ Sci B
Zhang M, Li Y, Lin H, Yu T, Xia F, Chatoo M, Li K, Yu H, Nevo E, DU J, Zhao Y, Chen X.   +11 more
europepmc   +1 more source

Targeting E3 ubiquitin ligases: Mechanistic breakthroughs and novel clinical translation pathways for tumor radioimmunotherapy. [PDF]

Mol Cancer
Yang Q, Xing X, Wang Y, Wang X, Han Y, Ren J, Zhang Z, Tang J, Zhao J.   +8 more
europepmc   +1 more source

MDM2 Alters Cellular Iron Homeostasis by Promoting the Degradation of Proteins Involved in Iron Storage and Iron Export. [PDF]

Curr Issues Mol Biol
Shi Y, Zhang J.
europepmc   +1 more source

RING finger E3 ubiquitin ligases: novel therapeutic opportunities in melanoma. [PDF]

Cell Mol Biol Lett
Zhang JF, Li LT, Yang YY, Zhang SC, Gao C, Zhu X, Xin H, Li XY.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

P53 Mdm2 Inhibitors

Current Pharmaceutical Design, 2012
The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a
Kareem, Khoury, Alex, Dömling
openaire   +4 more sources

MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation

Cancer Discovery, 2023
Summary: In this issue of Cancer Discovery, Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53 ...
Sylvain Peuget, Galina Selivanova
openaire   +2 more sources